Cargando…
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK–ERK signaling. This does not occur when oncogenic BRAF is inhibited, demonstrati...
Autores principales: | Heidorn, Sonja J., Milagre, Carla, Whittaker, Steven, Nourry, Arnaud, Niculescu-Duvas, Ion, Dhomen, Nathalie, Hussain, Jahan, Reis-Filho, Jorge S., Springer, Caroline J., Pritchard, Catrin, Marais, Richard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872605/ https://www.ncbi.nlm.nih.gov/pubmed/20141835 http://dx.doi.org/10.1016/j.cell.2009.12.040 |
Ejemplares similares
-
Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
por: Bhargava, Ajay, et al.
Publicado: (2016) -
Oncogenic RAS drives the CRAF‐dependent extracellular vesicle uptake mechanism coupled with metastasis
por: Choi, Dongsic, et al.
Publicado: (2021) -
Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
por: Chatelle, Claire V., et al.
Publicado: (2016) -
CRAF R391W is a melanoma driver oncogene
por: Atefi, Mohammad, et al.
Publicado: (2016) -
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds
por: Niculescu-Duvaz, Dan, et al.
Publicado: (2010)